Table 2 Treatment patterns and resource utilisation in the treatment and post-treatment follow-up of cervical cancer (percentages are average values based on experts’ responses)
From: Cost-effectiveness of human papillomavirus vaccination in Germany
Cervical cancer stage (FIGO classification) or treatment phase | Treatment patterns and resource utilisation | |
|---|---|---|
FIGO IA1 | Conisation | 60% |
Conisation with pelvic lymph node dissection | 10% | |
Simple hysterectomy | 20% | |
Simple hysterectomy with pelvic lymph node dissection | 10% | |
FIGO IA2 | Conisation with pelvic lymph node dissection | 20% |
Radical trachelectomy with pelvic lymph node dissection | 10% | |
Simple hysterectomy | 10% | |
Simple hysterectomy with pelvic lymph node dissection | 60% | |
FIGO IB1 | Radical hysterectomy with pelvic lymph node dissection | 64% |
Radical hysterectomy with pelvic lymph node dissection and adjuvant chemoradiotherapy | 16% | |
Radical trachelectomy with pelvic lymph node dissection | 5% | |
Chemoradiotherapy | 15% | |
FIGO IB2 | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 49% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 21% | |
Chemoradiotherapy | 30% | |
FIGO IIA | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 35% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 15% | |
Chemoradiotherapy | 50% | |
FIGO IIB | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 12% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 18% | |
Chemoradiotherapy | 70% | |
FIGO IIIA | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 2% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 8% | |
Chemoradiotherapy | 90% | |
FIGO IIIB | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 2% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 8% | |
Chemoradiotherapy | 90% | |
FIGO IVA | Radical hysterectomy with pelvic and paraaortic lymph node dissection | 2% |
Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy | 8% | |
Chemoradiotherapy | 80% | |
Exenteration | 2% | |
Exenteration and adjuvant chemoradiotherapy | 8% | |
FIGO IVB | Chemoradiotherapy | 40% |
Palliative chemotherapy | 60% | |
Post-treatment follow-up | Outpatient visits, Pap-smears, and pelvic and abdominal ultrasonography | 100% |
Hormone replacement therapy (women <50Â years) | 50% | |
Manual lymphatic drainage and medical compression tights | 10–30% | |